BATT, Douglas G.,BERTRAND, Myra Beaudoin,DELUCCA, George V.,GALELLA, Michael A.,KO, Soo Sung,LANGEVINE, Charles M.,LIU, Qingjie,SHI, Qing,SRIVASTAVA, Anurag S.,TINO, Joseph A.,WATTERSON, Scott Hunter
申请号：
TN2015000529
公开号：
TN2015000529A1
申请日:
2014.06.25
申请国别(地区):
TN
年份:
2017
代理人:
摘要：
Disclosed are compounds of Formula (1) wherein: the two dotted lines represent either two single or two double bonds； Q is: R<；sub>；1<；/sub>； is F, Cl, CN, or CH<；sub>；3<；/sub>；； R<；sub>；2<；/sub>； is Cl or CH<；sub>；3<；/sub>；； R<；sub>；3<；/sub>； is C(CH<；sub>；3<；/sub>；)<；sub>；2<；/sub>；OH or CH<；sub>；2<；/sub>；CH<；sub>；2<；/sub>；OH； R<；sub>；a<；/sub>； is H or CH<；sub>；3<；/sub>；； each R<；sub>；6<；/sub>； is independently F, Cl, CH<；sub>；3<；/sub>；, and/or OCH<；sub>；3<；/sub>；； and n is zero, l, or 2. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
